{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Ma Y"],"funding":["NCI NIH HHS"],"pagination":["962-70"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC3831028"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["6(9)"],"pubmed_abstract":["The clinical application of siRNA is limited largely by the lack of efficient, cell-specific delivery systems. Antibodies are attractive delivery vehicles for targeted therapy due to their high specificity. In this study we describe the use of a humanized monoclonal antibody (mAb), hu3S193, against Lewis-Y (Le(y)), as a delivery vehicle for STAT3 siRNA. This mAb is rapidly internalized into Le(y)-expressing cancer cells via antigen recognition, and when coupled to STAT3 siRNA, a potentially powerful molecularly targeted delivery agent is created. Selective silencing of STAT3 is associated with tumor suppression. Two hu3S193 based siRNA delivery systems using STAT3 siRNA as a prototype were developed and tested in Le(y)-positive cancer cells: (a) a covalent construct based on a reductive di"],"journal":["ACS chemical biology"],"pubmed_title":["Humanized Lewis-Y specific antibody based delivery of STAT3 siRNA."],"pmcid":["PMC3831028"],"funding_grant_id":["P30 CA033572","R01 CA055652"],"pubmed_authors":["Pillay V","Scott AM","Horne DA","Simpson AJ","Swiderski PM","Ma Y","Kowolik CM","Caballero OL","Yu H","Kortylewski M","Jove R","Lee FT"],"additional_accession":[]},"is_claimable":false,"name":"Humanized Lewis-Y specific antibody based delivery of STAT3 siRNA.","description":"The clinical application of siRNA is limited largely by the lack of efficient, cell-specific delivery systems. Antibodies are attractive delivery vehicles for targeted therapy due to their high specificity. In this study we describe the use of a humanized monoclonal antibody (mAb), hu3S193, against Lewis-Y (Le(y)), as a delivery vehicle for STAT3 siRNA. This mAb is rapidly internalized into Le(y)-expressing cancer cells via antigen recognition, and when coupled to STAT3 siRNA, a potentially powerful molecularly targeted delivery agent is created. Selective silencing of STAT3 is associated with tumor suppression. Two hu3S193 based siRNA delivery systems using STAT3 siRNA as a prototype were developed and tested in Le(y)-positive cancer cells: (a) a covalent construct based on a reductive di","dates":{"release":"2011-01-01T00:00:00Z","publication":"2011 Sep","modification":"2025-04-04T19:32:08.366Z","creation":"2019-03-27T03:08:42Z"},"accession":"S-EPMC3831028","cross_references":{"pubmed":["21766840"],"doi":["10.1021/cb200176v"]}}